DrugPatentWatch Archives
Click here to return to the current data set
|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: JAKAFI
Summary for Tradename: JAKAFI
|
| |||||||||
Clinical Trials for: JAKAFIRuxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Status: Not yet recruiting Condition: Leukemia Ruxolitinib Prior to Transplant in Patients With Myelofibrosis Status: Recruiting Condition: Primary Myelofibrosis; Post Polycythemia Vera Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Status: Recruiting Condition: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia Status: Active, not recruiting Condition: Polycythemia Vera; Essential Thrombocythemia Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Status: Active, not recruiting Condition: Myelofibrosis; Polycythemia Vera; Thrombocytosis A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis Status: Completed Condition: Plaque Psoriasis Phase l/II Study of Ruxolitinib for Acute Leukemia Status: Active, not recruiting Condition: Leukemia Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer Status: Terminated Condition: Metastatic Prostate Cancer A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Status: Recruiting Condition: Myelomonocytic Leukemia Ruxolitinib and Lenalidomide for Patients With Myelofibrosis Status: Recruiting Condition: Myeloproliferative Diseases Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET; ORAL | 202192 | Nov 16, 2011 | RX | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET; ORAL | 202192 | Nov 16, 2011 | RX | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET; ORAL | 202192 | Nov 16, 2011 | RX | No | 7,598,257 | Y | Y | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET; ORAL | 202192 | Nov 16, 2011 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc